Cibus (NASDAQ:CBUS) Announces Earnings Results

Cibus (NASDAQ:CBUS) announced its quarterly earnings data on Thursday. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09), FiscalAI reports. Cibus had a negative return on equity of 287.03% and a negative net margin of 2,258.89%. The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $1.30 million.

Here are the key takeaways from Cibus’ conference call:

• Bio-fragrance opportunity expanded under a direct-sales model: Cibus estimates up to $100 million in peak annual revenue across eight ingredients, with projected gross margins of roughly 50%–70% and no expected manufacturing CapEx. Its first two ingredients are approved for the partner’s products and scale-up has begun, but revenue still depends on formulation success and purchase orders.
• Rice traits advanced toward customer testing and commercialization: Initial Latin American trials showed positive performance, and Interoc has planted Cibus-edited varieties in Ecuador, with results expected in the first quarter of 2027. Cibus targets a Latin American launch as early as 2028, though timing depends on trial results and commercialization planning.
• Near-term financing remains a significant risk: Cibus had $10.7 million in cash at quarter-end and expects it to fund planned expenses only into early Q1 2027; management said additional capital will be needed in the near term. The company reported a $21.9 million quarterly net loss.
• Spending discipline improved, while partner-funded programs progressed: Nine-month operating cash use fell about 19% year over year, and quarterly operating expenses declined roughly $2.7 million. Work began on partner-funded Indian mustard traits, while the U.K. light leaf spot program remained on schedule and pod-shatter material received approval for trial planting in England.

Cibus Trading Down 6.0%

Shares of NASDAQ:CBUS traded down $0.07 on Thursday, reaching $1.09. 167,542 shares of the company were exchanged, compared to its average volume of 353,615. Cibus has a 1-year low of $1.07 and a 1-year high of $4.19. The firm has a market cap of $83.31 million, a price-to-earnings ratio of -0.66 and a beta of 1.65. The company has a 50-day moving average of $1.45 and a 200-day moving average of $1.83.

Analyst Ratings Changes

Several analysts have recently weighed in on CBUS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cibus in a report on Friday, September 25th. Wall Street Zen downgraded shares of Cibus from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

Cibus Company Profile

Cibus, Inc. (NASDAQ: CBUS) is an agricultural biotechnology company focused on developing gene-edited crop traits. Its technology is designed to improve the performance, resilience and sustainability of important crops by making targeted changes to plant genetics without introducing foreign DNA. The company’s proprietary Rapid Trait Development System (RTDS) supports the development of traits for crops including canola, rice, soybeans and wheat. Cibus has pursued applications such as herbicide tolerance, pod-shatter reduction and resistance to diseases and other environmental stresses, with the goal of helping growers improve yields, reduce crop losses and use agricultural inputs more efficiently.